
Home » Medicago collaborates with U.S. Army Medical Research Institute of Infectious Diseases for Ebola vaccine
Medicago collaborates with U.S. Army Medical Research Institute of Infectious Diseases for Ebola vaccine
May 27, 2011
Medicago, a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and virus-like particles (VLPs), has entered into a research collaboration agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) for the development of a plant-based VLP vaccine candidate for the prevention of Ebola. Ebola is a very serious hemorrhagic fever virus for which no licensed treatment or vaccine exists.
"We are currently working on several other important infectious disease targets outside of influenza," said Louis Vezina, Chief Scientific Officer of Medicago. "Our expertise in the development of VLP vaccines using our transient expression system, coupled with USAMRIID's experience and knowledge creates an ideal combination for the rapid development of a new generation of efficacious and competitive VLP vaccines."
Upcoming Events
-
14Apr